The device, worn on the stomach, senses when a person stops breathing and injects naloxone — a lifesaving antidote that can restore respiration.
A regular, affordable antibiotic treatment has been found to significantly reduce the risk of underlying rheumatic heart disease progression in children.
The treatment can make cancerous cells up to 30% more receptive to radiotherapy while simultaneously reducing adverse side effects that limit quality of life.
The smart wearable sensor can conduct real-time, point-of-care assessment of chronic wounds wirelessly via an app.
The TGA provisionally approves a booster dose of Pfizer's vaccine for individuals 18 years and older, while advisers to the US FDA recommend the vaccine for children aged 5–11.
The $96 million pilot facility will develop mRNA and RNA drugs and vaccines, in order to better combat disease and save lives.
To fast-track time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies.
The Precision Nanosystems NanoAssemblr is a platform of technologies designed to encapsulate a drug or genetic material.
An existing drug — used to treat constipation — may be able to boost our ability to think more clearly.
The Australian Government will purchase 300,000 courses of the company's promising oral COVID-19 treatment, should it receive approval from the TGA.
When combined with immunotherapy the drugs managed to stop the cancer growth long term, and in some cases the tumours disappeared completely.
The Health Innovation Centre will include a flagship cardiovascular disease-focused research accelerator, HeartLabs, and a new focal point for clinical trials.
The Australian Government has secured an additional one million doses of Moderna's COVID-19 vaccine, recently approved for adolescents aged 12 to 17 years.
The landscape has shifted from a hopeless pipedream to firm steps and to the creation of such an ecosystem, from the unlikeliest places.
Pfizer's COVID-19 vaccine will soon be available for all Australians 12 years and above, and the TGA grants provisional approval for a novel monoclonal antibody treatment.